AIM ImmunoTech highlights DURIPANC trial testing Ampligen plus AstraZeneca’s Imfinzi in metastatic pancreatic cancer maintenance therapy
AIM•Final dosing has finished in the DURIPANC trial testing Ampligen with AstraZeneca’s Imfinzi after first-line chemotherapy for metastatic pancreatic cancer. Primary and secondary endpoint results have not been presented.
1. Trial dosing completed
AIM ImmunoTech highlighted the DURIPANC trial, which is testing Ampligen with AstraZeneca’s Imfinzi as maintenance therapy following first-line chemotherapy for metastatic pancreatic cancer. Final dosing has finished, but primary and secondary endpoint results have not been presented. The strategy aims to sustain disease control without new chemotherapy; exploratory observations from a Netherlands named-patient program helped guide biomarker work but do not establish efficacy.
